Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.

Authors

Leonardo Quarta, Michele Petix, Maximilian Filzmayer, Filippo Orlandi, Federico Polverino, Jordan A Goyal, Matteo Ferro, Felix K H Chun, Salvatore Micali, Nicola Longo, Shahrokh F Shariat, Francesco Barletta, Armando Stabile, Giorgio Gandaglia, Francesco Montorsi, Fred Saad, Alberto Briganti, Pierre I Karakiewicz

Published in

The Prostate. Jun 23, 2026. Epub Jun 23, 2026.

Abstract

Randomized trials demonstrated improved survival in metastatic prostate cancer (mPCa) with the adoption of several systemic therapies. However, real-world data validating this effect and quantifying its magnitude in years of life lost (YLL) according to race/ethnicity are unavailable.
In surveillance, epidemiology, and end results (SEER) database (2004-2021), Caucasian, African American, Hispanic, and Asian/Pacific Islander mPCa patients aged 40-80 years treated in androgen deprivation therapy (ADT, 2004-2012), docetaxel (2013-2016), abiraterone (2017-2018), and androgen receptor pathway inhibitor (ARPI, 2019-2021) eras were identified. Age- and sex-matched controls were generated (Social Security Administration life tables and Monte Carlo simulation). YLL were quantified for mPCa patients and controls.
Overall, 36,658 mPCa patients were identified: 22,725 (62.0%) Caucasians, 6956 (19.0%) African Americans, 4785 (13.0%) Hispanics, and 2192 (6.0%) Asians/Pacific Islanders. In the ADT era, YLL values were 10.7 in African Americans, 9.0 in Hispanics, 8.4 in Caucasians, and 6.5 in Asians/Pacific Islanders. In the docetaxel era, YLL values were 9.4 in African Americans, 8.4 in Hispanics, 7.3 in Caucasians, and 6.2 in Asians/Pacific Islanders. In the abiraterone era, YLL values were 8.4 in African Americans, 6.3 in Hispanics, 5.4 in Caucasians, and 4.4 in Asians/Pacific Islanders. In the ARPI era, YLL values were 4.3 in African Americans, 3.6 in Hispanics, 2.7 in Caucasians, and 1.7 in Asians/Pacific Islanders.
YLL values decreased with each novel treatment era, in all race/ethnicity groups. The most pronounced decrease in YLL values occurred with the introduction of ARPIs, in all race/ethnicity groups. Despite those survival advances, African Americans were invariably disadvantaged as evidenced by the highest YLL values.

PMID:
42335306
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.